Literature DB >> 34050868

Maintenance of Endoplasmic Reticulum Protein Homeostasis in Cancer: Friend or Foe.

Mari McMahon1,2,3, Afshin Samali3, Eric Chevet4,5.   

Abstract

The endoplasmic reticulum, as the site of synthesis for proteins in the secretory pathway has evolved select machineries to ensure the correct folding and modification of proteins. However, sometimes these quality control mechanisms fail and proteins are misfolded. Other factors, such as nutrient deprivation, hypoxia or an increased demand on protein synthesis can also cause the accumulation of unfolded or misfolded proteins in the endoplasmic reticulum. There are mechanisms that recognise and deal with this accumulation of protein through degradation and/or export. Many diseases are associated with aberrant quality control mechanisms, and among these, cancer has emerged as a group of diseases that rely on endoplasmic reticulum homeostasis to sustain development and growth. The knowledge of how protein quality control operates in cancer has identified opportunities for these pathways to be pharmacologically targeted, which could lead to newer or more effective treatments in the future.

Entities:  

Keywords:  Endoplasmic reticulum; cancer; proteostasis; quality control

Year:  2021        PMID: 34050868     DOI: 10.1007/978-3-030-67696-4_10

Source DB:  PubMed          Journal:  Prog Mol Subcell Biol        ISSN: 0079-6484


  48 in total

1.  Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development.

Authors:  Jeffrey M Axten; Stuart P Romeril; Arthur Shu; Jeffrey Ralph; Jesús R Medina; Yanhong Feng; William Hoi Hong Li; Seth W Grant; Dirk A Heerding; Elisabeth Minthorn; Thomas Mencken; Nathan Gaul; Aaron Goetz; Thomas Stanley; Annie M Hassell; Robert T Gampe; Charity Atkins; Rakesh Kumar
Journal:  ACS Med Chem Lett       Date:  2013-08-12       Impact factor: 4.345

2.  Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).

Authors:  Jeffrey M Axten; Jesús R Medina; Yanhong Feng; Arthur Shu; Stuart P Romeril; Seth W Grant; William Hoi Hong Li; Dirk A Heerding; Elisabeth Minthorn; Thomas Mencken; Charity Atkins; Qi Liu; Sridhar Rabindran; Rakesh Kumar; Xuan Hong; Aaron Goetz; Thomas Stanley; J David Taylor; Scott D Sigethy; Ginger H Tomberlin; Annie M Hassell; Kirsten M Kahler; Lisa M Shewchuk; Robert T Gampe
Journal:  J Med Chem       Date:  2012-08-08       Impact factor: 7.446

Review 3.  PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development.

Authors:  Yiwen Bu; J Alan Diehl
Journal:  J Cell Physiol       Date:  2016-03-06       Impact factor: 6.384

4.  Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma.

Authors:  Gregor Auf; Arnaud Jabouille; Sylvaine Guérit; Raphaël Pineau; Maylis Delugin; Marion Bouchecareilh; Noël Magnin; Alexandre Favereaux; Marlène Maitre; Timo Gaiser; Andreas von Deimling; Marcus Czabanka; Peter Vajkoczy; Eric Chevet; Andreas Bikfalvi; Michel Moenner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-11       Impact factor: 11.205

5.  Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.

Authors:  Bojan Bujisic; Aude De Gassart; Rémy Tallant; Olivier Demaria; Léa Zaffalon; Sonia Chelbi; Michel Gilliet; Francesco Bertoni; Fabio Martinon
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113

6.  High epiregulin expression in human U87 glioma cells relies on IRE1α and promotes autocrine growth through EGF receptor.

Authors:  Gregor Auf; Arnaud Jabouille; Maylis Delugin; Sylvaine Guérit; Raphael Pineau; Sophie North; Natalia Platonova; Marlène Maitre; Alexandre Favereaux; Peter Vajkoczy; Masaharu Seno; Andreas Bikfalvi; Dmitri Minchenko; Oleksandr Minchenko; Michel Moenner
Journal:  BMC Cancer       Date:  2013-12-13       Impact factor: 4.430

7.  XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.

Authors:  Dimitrios Iliopoulos; Qing Zhang; Qianzi Tang; Xi Chen; Matthew B Greenblatt; Maria Hatziapostolou; Elgene Lim; Wai Leong Tam; Min Ni; Yiwen Chen; Junhua Mai; Haifa Shen; Dorothy Z Hu; Stanley Adoro; Bella Hu; Minkyung Song; Chen Tan; Melissa D Landis; Mauro Ferrari; Sandra J Shin; Myles Brown; Jenny C Chang; X Shirley Liu; Laurie H Glimcher
Journal:  Nature       Date:  2014-03-23       Impact factor: 49.962

Review 8.  Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications.

Authors:  Aitor Almanza; Antonio Carlesso; Chetan Chintha; Stuart Creedican; Dimitrios Doultsinos; Brian Leuzzi; Andreia Luís; Nicole McCarthy; Luigi Montibeller; Sanket More; Alexandra Papaioannou; Franziska Püschel; Maria Livia Sassano; Josip Skoko; Patrizia Agostinis; Jackie de Belleroche; Leif A Eriksson; Simone Fulda; Adrienne M Gorman; Sandra Healy; Andrey Kozlov; Cristina Muñoz-Pinedo; Markus Rehm; Eric Chevet; Afshin Samali
Journal:  FEBS J       Date:  2018-08-04       Impact factor: 5.542

Review 9.  Structure and Molecular Mechanism of ER Stress Signaling by the Unfolded Protein Response Signal Activator IRE1.

Authors:  Christopher J Adams; Megan C Kopp; Natacha Larburu; Piotr R Nowak; Maruf M U Ali
Journal:  Front Mol Biosci       Date:  2019-03-12

10.  The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.

Authors:  Daniel R Carrasco; Kumar Sukhdeo; Marina Protopopova; Raktim Sinha; Miriam Enos; Daniel E Carrasco; Mei Zheng; Mala Mani; Joel Henderson; Geraldine S Pinkus; Nikhil Munshi; James Horner; Elena V Ivanova; Alexei Protopopov; Kenneth C Anderson; Giovanni Tonon; Ronald A DePinho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.